May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Treatment of Sjogren's Syndrome With Anti–P–selectin Glycoprotein Ligand–1 Monoclonal Antibody in NOD Mice
C.–P. Lin; C.–H. Yang; F.–A. Lin; W.–L. Chen
Author Affiliations & Notes
  • C.–P. Lin
    Department of Ophthalmology, National Taiwan Univ Hospital, Taipei, Taiwan Republic of China
  • C.–H. Yang
    Department of Ophthalmology, National Taiwan Univ Hospital, Taipei, Taiwan Republic of China
  • F.–A. Lin
    Department of Ophthalmology, National Taiwan Univ Hospital, Taipei, Taiwan Republic of China
  • W.–L. Chen
    Department of Ophthalmology, National Taiwan Univ Hospital, Taipei, Taiwan Republic of China
  • Footnotes
    Commercial Relationships  C. Lin, None; C. Yang, None; F. Lin, None; W. Chen, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 986. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Treatment of Sjogren's Syndrome With Anti–P–selectin Glycoprotein Ligand–1 Monoclonal Antibody in NOD Mice
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      C.–P. Lin, C.–H. Yang, F.–A. Lin, W.–L. Chen; Treatment of Sjogren's Syndrome With Anti–P–selectin Glycoprotein Ligand–1 Monoclonal Antibody in NOD Mice . Invest. Ophthalmol. Vis. Sci. 2005;46(13):986.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose: P–selectin glycoprotein ligand–1 has been shown to be involved in T lymphocyte traficking. Its monoclonal antibody has been shown to induce apoptosis in activated T–cells. To study the effect of anti–CD162 (p–selectin glycoprotein ligand–1) monocloanl antibody on the course of Sjogren's syndrome in NOD mice. Methods: Anti–CD162 monoclonal antibody was raised in hamster and was injected intraperitoneally in treatment goups of NOD mice at the age of 8, 9 and 10 weeks. Total hamster IgG was used in control group. Tear secretion, both basal and stimulated with pilocarpine, and urine sugar were measured at different time points until the age of 30 weeks. Histopathology of lacrimal gland, salivary gland and pancrease was also studied. Results: Tear secretion was preserved in treatment group at 22, 25 and 30 weeks of age. Histopathology showed significant less lymphocytic infiltraion in lacrimal gland, salivary gland and pancreatic islet. In treatment group, 80% and 70% of mice remained diabetes free at the age of 22 and 30 weeks respectively. Only 20% of control group remained diabetes free. Conclusions: Anti–CD162 monocloanl antibody could prevent Sjogren syndrome as well as diabetes in NOD mouse, possibly by suppressing lymphocytic infiltraion.

Keywords: autoimmune disease • cornea: tears/tear film/dry eye • immunomodulation/immunoregulation 
© 2005, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept